Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
11 nov. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
-Preclinical data highlight Jounce’s approach to identify potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064- -Enrollment in Phase 1 monotherapy...
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
06 nov. 2020 07h00 HE
|
Jounce Therapeutics, Inc.
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT...
Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
02 sept. 2020 16h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
07 août 2020 06h30 HE
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
04 juin 2020 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07 août 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
23 juil. 2019 16h00 HE
|
Jounce Therapeutics, Inc.
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...
Jounce Therapeutics Reports First Quarter 2019 Financial Results
08 mai 2019 06h30 HE
|
Jounce Therapeutics, Inc.
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and...
Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
01 mai 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
03 avr. 2019 08h02 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...